Scopus Biopharma Shares Spike Higher, Not Seeing News From The Co.; Stock Receiving Social Media Attention As A Low-Float Play
https://twitter.com/ACInvestorBlog/status/1422999323340587013
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET Friday, 117 stocks made new 52-week lows.
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 22)
Scopus BioPharma Names Alan Horsager President Of Co
Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical needs, today announced a new
Scopus BioPharma Adds Oligonucleotide Cancer Therapeutics With Olimmune Acquisition
Scopus BioPharma Inc (NASDAQ:SCPS) has acquired Los Angeles-based Olimmune Inc for an undisclosed amount. Olimmune is a developer of oligonucleotide immunotherapies for treatment-resistant…
60 Biggest Movers From Yesterday
Gainers
Lizhi Inc. (NASDAQ: LIZI) shares surged 57.6% to close at $6.84 on Wednesday.
52 Biggest Movers From Yesterday
Gainers
Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA, its distinctive immuno-oncology RNA therapy for the treatment of multiple cancers.
Why Scopus BioPharma’s Stock Is Surging Today
Scopus BioPharma (NASDAQ:SCPS) shares are trading higher after the company announced the FDA has approved its IND application for CpG-STAT3siRNA, the company's distinctive immuno-oncology RNA therapy for the treatment of multiple cancers.